Top Wall Street Stories: Planet Payment, Inc. (NASDAQ:PLPM), Xplore Technologies Corp. (NASDAQ:XPLR), Camden National Corp. (NASDAQ:CAC), STMicroelectronics NV (NYSE:STM), Transgenomic Inc. (NASDAQ:TBIO)

Planet Payment, Inc. (NASDAQ:PLPM) belongs to Financial sector. Its net profit margin is 10.40% and weekly performance is 3.29%. On last trading day company shares ended up $2.42. Planet Payment, Inc. (NASDAQ:PLPM) distance from 50-day simple moving average (SMA50) is 3.32%. Zacks upgraded shares of Planet Payment (NASDAQ:PLPM) from a hold rating to a buy rating in a research note released on Thursday morning. They currently have $3.00 target price on the stock.

Xplore Technologies Corp. (NASDAQ:XPLR) shares moved down -2.03% in last trading session and ended the day at $5.78. XPLR Gross Margin is 33.60% and its return on assets is 0.80%. Xplore Technologies Corp. (NASDAQ:XPLR) quarterly performance is -7.37%. On July, it was reported Xplore Technologies Corp. (NASDAQ: XPLR), will deploy almost 600 Motion C5 tablet PCs as part of an innovative “Intelligent Ambulance” project that has been proven to save lives.

On 13 July, Camden National Corp. (NASDAQ:CAC) shares moved up 0.65% and was closed at $38.99. CAC EPS growth in last 5 year was 1.90%. Camden National Corp. (NASDAQ:CAC) year to date (YTD) performance is -0.62%. Camden National Corporation (NASDAQ:CAC) cash dividend payment of $0.3 per share is scheduled to be paid on July 31, 2015.

STMicroelectronics NV (NYSE:STM) ended the last trading day at $7.84. Company weekly volatility is calculated as 2.31% and price to cash ratio as 3.08. STMicroelectronics NV (NYSE:STM) showed a weekly performance of -1.75%. STMicroelectronics (NYSE: STM), announced that it will release second quarter 2015 earnings before the opening of trading on the European Stock Exchanges on Thursday July 23, 2015.

Transgenomic Inc. (NASDAQ:TBIO) shares moved up 4.38% in last trading session and ended the day at $1.43. TBIO Gross Margin is 37.40% and its return on assets is -44.30%. On 1st July, Transgenomic, Inc. (NASDAQ:TBIO), announced that its ICEme™ Mutation Enrichment Kits for cancer research are now commercially available to researchers worldwide. The kits, which were launched on June 30, 2015, are based on Transgenomic’s Multiplexed ICE COLD-PCR™ (MX-ICP) technology.

Leave a Reply

Your email address will not be published. Required fields are marked *